ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
61 553,96
1,24%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ardelyx Inc (ARDX)

  7. Ardelyx Inc (ARDX) Actualités

ARDX

Ardelyx (ARDX)

Ardelyx Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ARDX
DateHeureSourceTitreSymboleSociété
09/05/202422h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARDXArdelyx Inc
07/05/202414h01GlobeNewswire Inc.Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week ConferenceNASDAQ:ARDXArdelyx Inc
02/05/202422h02GlobeNewswire Inc.Ardelyx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARDXArdelyx Inc
01/05/202414h00GlobeNewswire Inc.Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical MeetingsNASDAQ:ARDXArdelyx Inc
18/04/202414h00GlobeNewswire Inc.Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024NASDAQ:ARDXArdelyx Inc
28/03/202421h05GlobeNewswire Inc.Ardelyx, Inc. Reports Employment Inducement GrantsNASDAQ:ARDXArdelyx Inc
25/03/202413h00GlobeNewswire Inc.Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and StrategyNASDAQ:ARDXArdelyx Inc
05/03/202422h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDXArdelyx Inc
27/02/202414h00GlobeNewswire Inc.Ardelyx to Participate at the Cowen 44th Annual Health Care ConferenceNASDAQ:ARDXArdelyx Inc
22/02/202422h40Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ARDXArdelyx Inc
22/02/202422h01GlobeNewswire Inc.Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:ARDXArdelyx Inc
22/02/202412h05IH Market NewsU.S. Futures Surge on Nvidia’s Stellar Performance, Global Markets Respond PositivelyNASDAQ:ARDXArdelyx Inc
13/02/202420h12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARDXArdelyx Inc
01/02/202414h00GlobeNewswire Inc.Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024NASDAQ:ARDXArdelyx Inc
08/01/202414h00GlobeNewswire Inc.Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic PrioritiesNASDAQ:ARDXArdelyx Inc
03/01/202414h03GlobeNewswire Inc.Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8NASDAQ:ARDXArdelyx Inc
21/11/202314h01GlobeNewswire Inc.Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:ARDXArdelyx Inc
15/11/202322h02GlobeNewswire Inc.XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric HyperphosphatemiaNASDAQ:ARDXArdelyx Inc
13/11/202322h02GlobeNewswire Inc.Ardelyx Announces Departure of Board MemberNASDAQ:ARDXArdelyx Inc
10/11/202314h05GlobeNewswire Inc.Ardelyx to Participate at the Jefferies London Healthcare ConferenceNASDAQ:ARDXArdelyx Inc
06/11/202314h00GlobeNewswire Inc.Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United StatesNASDAQ:ARDXArdelyx Inc
03/11/202313h00GlobeNewswire Inc.Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023NASDAQ:ARDXArdelyx Inc
31/10/202312h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARDXArdelyx Inc
31/10/202312h00GlobeNewswire Inc.Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue GuidanceNASDAQ:ARDXArdelyx Inc
23/10/202314h07GlobeNewswire Inc.Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023NASDAQ:ARDXArdelyx Inc
18/10/202322h02GlobeNewswire Inc.Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023NASDAQ:ARDXArdelyx Inc
18/10/202321h35AllPennyStocks.comBiotech Finds Mid-Week Success Following FDA AnnouncementNASDAQ:ARDXArdelyx Inc
18/10/202315h03IH Market NewsWednesday’s Wall Street Highlights: ASML, Nvidia, United Airlines, Viking Therapeutics, P&G, and MoreNASDAQ:ARDXArdelyx Inc
18/10/202314h30Dow Jones NewsArdelyx Shares Rally Premarket on FDA Approval of XphozahNASDAQ:ARDXArdelyx Inc
18/10/202301h44Dow Jones NewsArdelyx Gets FDA OK for Add-On Therapy for Kidney Disease PatientsNASDAQ:ARDXArdelyx Inc
 Showing the most relevant articles for your search:NASDAQ:ARDX

Dernières Valeurs Consultées

NYSE
JPM
JP Morgan Chase
NYSE
DIS
Walt Disney
EU
GLE
Societe Generale
NASDAQ
AAPL
Apple
EU
RNO
Renault
EU
ML
Michelin
SPI
SP500
S&P 500
EU
VK
Vallourec
EU
ACA
Credit Agricole
FTSE
UKX
FTSE 100
USI
USTECH100
US Tech 100
EU
CS
Axa
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés